Is there any cardioprotective role of Taurine during cold ischemic period following global myocardial ischemia?

• Published in: Journal of cardiothoracic surgery Vol. 6; no. 1; p. 31
• Main Authors: Sahin, Mehmet A, Yucel, Orhan, Guler, Adem, Doganci, Suat, Jahollari, Artan, Cingoz, Faruk, Arslan, Sıddık, Gamsizkan, Mehmet, Yaman, Halil, Demirkilic, Ufuk
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 18.03.2011; BioMed Central; BMC
• Subjects: Animals; Antioxidants; Care and treatment; Catalase - metabolism; Cold; Diagnosis; Disease Models, Animal; Dose-Response Relationship, Drug; Feeds; Glutathione Peroxidase - metabolism; Health aspects; Ischemia; Ischemic Preconditioning, Myocardial; Laboratory animals; Lipid Peroxidation; Male; Myocardial ischemia; Myocardial Reperfusion Injury - metabolism; Myocardial Reperfusion Injury - physiopathology; Myocardial Reperfusion Injury - prevention & control; Myocardium - enzymology; Myocardium - pathology; Rats; Risk factors; Rodents; Spectrophotometry; Superoxide Dismutase - metabolism; Surgery; Taurine; Taurine - administration & dosage; Taurine - therapeutic use; Thoracic surgery; Treatment Outcome; Turkey
• ISSN: 1749-8090; 1749-8090
• DOI: 10.1186/1749-8090-6-31

The aim of the present study was to investigate the cardioprotective effect of Taurine on the donor hearts during cold ischemic period. 32 rats were divided into four groups (sham, taurine, ischemia, treatment group, 8 rats in each). All rats were fed with rat food for three weeks. Taurine and treatment groups were given a 200 mg/kg/day dose of Taurine by oral gavage besides rat feed. Cardiectomy was performed in all rats after three weeks. In ischemia and treatment groups, harvested hearts were kept in 0.9% sodium chloride at +4 degrees C for 5 hours. Tissue samples were taken from left ventricle in all groups. These samples were evaluated by histopathologic and biochemical examination. In the present study results of the biochemical and histopathological examination reveals the protective effects of Taurine. As a marker of lipid peroxidation, Malondialdehyde (MDA) levels in ischemia group were significantly higher than both Sham and Taurine groups. MDA values were recorded; 3.62 ± 0.197 in the sham group, 2.07 ± 0.751 in the Taurine group, 9.71 ± 1.439 in the ischemia group and 7.68 ± 1.365 in the treatment group. MDA levels decreased in treatment group. (p < 0.05) In accordance with MDA findings, while superoxide dismutase and glutathione peroxidase levels decreased in ischemia group, they increased in treatment group. (p < 0.05) There was no differences in Catalase (CAT) enzyme level between treatment and ischemia group (p = 1.000). CAT level results were recorded; 7.08 ± 0.609 in the sham group, 6.15 ± 0.119 in the Taurine group, 5.02 ± 0.62 in the ischemia group, and 5.36 ± 0.384 in the treatment group. Less intracellular edema and inflammatory cell reaction were observed in histologic examination in favor of treatment group. (p < 0.01) Taurine decreased myocardial damage during cold ischemic period following global myocardial ischemia.